{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:01:56Z","timestamp":1781456516774,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.humimm.2025.111620","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:42:55Z","timestamp":1765406575000},"page":"111620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belatacept suppresses B-cell subset alloresponses"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-3407","authenticated-orcid":false,"given":"Chethan","family":"Ashokkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustimbo","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehman","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8688-7695","authenticated-orcid":false,"given":"Brianna","family":"Spishock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon W","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-6694","authenticated-orcid":false,"given":"Rakesh","family":"Sindhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.humimm.2025.111620_b0005","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/ajt.14939","article-title":"Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: an analysis of the BENEFIT and BENEFIT-EXT trial cohorts","volume":"18","author":"Everly","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2025.111620_b0010","doi-asserted-by":"crossref","unstructured":"Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant. 2018 Jul;18(7):1774-1782. doi: 10.1111\/ajt.14738. Epub 2018 Apr 17. PMID: 29573335; PMCID: PMC6055813.","DOI":"10.1111\/ajt.14738"},{"key":"10.1016\/j.humimm.2025.111620_b0015","doi-asserted-by":"crossref","unstructured":"Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111\/ajt.14721. Epub 2018 Apr 2. PMID: 29509295; PMCID: PMC6055714.","DOI":"10.1111\/ajt.14721"},{"issue":"3","key":"10.1016\/j.humimm.2025.111620_b0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2025.111620_b0025","doi-asserted-by":"crossref","unstructured":"Leibler C, Thiolat A, H\u00e9nique C, Samson C, Pilon C, Tamagne M, Pirenne F, Vingert B, Cohen JL, Grimbert P. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. J Am Soc Nephrol. 2018 Mar;29(3):1049-1062. doi: 10.1681\/ASN.2017060679. Epub 2018 Jan 10. PMID: 29321143; PMCID: PMC5827599.","DOI":"10.1681\/ASN.2017060679"},{"issue":"1","key":"10.1016\/j.humimm.2025.111620_b0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12967-018-1678-1","article-title":"Is it possible to overcome issues of external validity in preclinical animal research? why most animal models are bound to fail","volume":"16","author":"Pound","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.humimm.2025.111620_b0035","first-page":"007","article-title":"Comparative Pharmacokinetics of drugs in Different Animal Species","volume":"11","author":"Stephen","year":"2023","journal-title":"J Pharmacol Toxicol Stud."},{"issue":"3","key":"10.1016\/j.humimm.2025.111620_b0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007890-200002150-00022","article-title":"Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen","volume":"69","author":"Sindhi","year":"2000","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.humimm.2025.111620_b0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/10799900152434385","article-title":"Cytokines and cell surface receptors as target end points of immunosuppression with cyclosporine a","volume":"21","author":"Sindhi","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"issue":"1\u20132","key":"10.1016\/j.humimm.2025.111620_b0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-1759(02)00326-5","article-title":"Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications","volume":"272","author":"Sindhi","year":"2003","journal-title":"J. Immunol. Methods"},{"issue":"9","key":"10.1016\/j.humimm.2025.111620_b0055","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2741\/1260","article-title":"Multiparametric effect: concentration analyses","volume":"1","author":"Sindhi","year":"2004","journal-title":"Front Biosci"},{"issue":"2","key":"10.1016\/j.humimm.2025.111620_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cyto.a.20200","article-title":"Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses","volume":"69","author":"Berry","year":"2006","journal-title":"Cytometry A"},{"issue":"5","key":"10.1016\/j.humimm.2025.111620_b0065","doi-asserted-by":"crossref","first-page":"15218","DOI":"10.1038\/srep15218","article-title":"Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens","volume":"16","author":"Ashokkumar","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.humimm.2025.111620_b0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-013-0153-2","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients","volume":"34","author":"Shen","year":"2014","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.humimm.2025.111620_b0075","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00919969","article-title":"The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39","volume":"13","author":"Marshall","year":"1993","journal-title":"J. Clin. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.humimm.2025.111620_b0080","first-page":"1","article-title":"Central role of CD40 and its ligand in B lymphocyte responses to T-dependent antigens","volume":"40","author":"Gordon","year":"1994","journal-title":"Cell. Mol. Biol. (Noisy-le-Grand)"},{"issue":"10","key":"10.1016\/j.humimm.2025.111620_b0085","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.4049\/jimmunol.154.10.4996","article-title":"The CD40 ligand expressed by human B cells costimulates B cell responses","volume":"154","author":"Grammer","year":"1995","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.humimm.2025.111620_b0090","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.4049\/jimmunol.163.8.4150","article-title":"Expression, regulation, and function of B cell-expressed CD154 in germinal centers","volume":"163","author":"Grammer","year":"1999","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2025.111620_b0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4049\/jimmunol.131.1.109","article-title":"B cells as antigen-presenting cells: the requirement for B cell activation","volume":"131","author":"Kakiuchi","year":"1983","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.humimm.2025.111620_b0100","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/TP.0b013e3181f995ce","article-title":"Allospecific CD154+ B cells associate with intestine allograft rejection in children","volume":"90","author":"Ashokkumar","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.humimm.2025.111620_b0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/TP.0b013e318229f752","article-title":"Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation","volume":"92","author":"Tsai","year":"2011","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.humimm.2025.111620_b0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/TP.0000000000001391","article-title":"Prevalence and Clinical Impact of Donor-specific Alloantibody among Intestinal Transplant Recipients","volume":"101","author":"Cheng","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2025.111620_b0115","doi-asserted-by":"crossref","unstructured":"Ningappa M, Ashokkumar C, Higgs BW, Sun Q, Jaffe R, Mazariegos G, Li D, Weeks DE, Subramaniam S, Ferrell R, Hakonarson H, Sindhi R. Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection. Am J Transplant. 2016 Feb;16(2):497-508. doi: 10.1111\/ajt.13509. Epub 2015 Dec 11. PMID: 26663361; PMCID: PMC5082419.","DOI":"10.1111\/ajt.13509"},{"issue":"3","key":"10.1016\/j.humimm.2025.111620_b0120","doi-asserted-by":"crossref","first-page":"e1589","DOI":"10.1097\/TXD.0000000000001589","article-title":"Enhanced Donor Antigen Presentation by B Cells Predicts Acute Cellular rejection and late Outcomes after Transplantation","volume":"10","author":"Ashokkumar","year":"2024","journal-title":"Transplant. Direct"},{"key":"10.1016\/j.humimm.2025.111620_b0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1146\/annurev.iy.08.040190.004013","article-title":"Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes","volume":"8","author":"Lanzavecchia","year":"1990","journal-title":"Annu. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.humimm.2025.111620_b0130","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1073\/pnas.89.17.8342","article-title":"Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells","volume":"89","author":"Levine","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.humimm.2025.111620_b0135","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1053\/gast.2000.20168","article-title":"Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states","volume":"119","author":"Telega","year":"2000","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.humimm.2025.111620_b0140","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: a Decade of Discovery and Diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2025.111620_b0145","doi-asserted-by":"crossref","unstructured":"Parsons RF, Larsen CP, Pearson TC, Badell IR. Belatacept and CD28 Costimulation Blockade: Preventing and Reducing Alloantibodies over the Long Term. Curr Transplant Rep. 2019 Dec;6(4):277-284. doi: 10.1007\/s40472-019-00260-3. Epub 2019 Nov 2. PMID: 32158639; PMCID: PMC7063534.","DOI":"10.1007\/s40472-019-00260-3"},{"issue":"1","key":"10.1016\/j.humimm.2025.111620_b0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-020-2138-x","article-title":"Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.humimm.2025.111620_b0155","doi-asserted-by":"crossref","first-page":"13816","DOI":"10.1038\/s41598-023-40700-w","article-title":"Belatacept inhibit human B cell germinal center development in immunodeficient mice","volume":"13","author":"Samson","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2025.111620_b0160","doi-asserted-by":"crossref","unstructured":"Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005 Jun 1;105(11):4390-8. doi: 10.1182\/blood-2004-11-4284. Epub 2005 Feb 8. PMID: 15701725; PMCID: PMC1895038.","DOI":"10.1182\/blood-2004-11-4284"},{"issue":"5","key":"10.1016\/j.humimm.2025.111620_b0165","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/ajt.12721","article-title":"Kidney transplant recipients treated with belatacept exhibit increased na\u00efve and transitional B cells","volume":"14","author":"Leibler","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2025.111620_b0170","doi-asserted-by":"crossref","unstructured":"Xu H, Samy KP, Guasch A, Mead SI, Ghali A, Mehta A, Stempora L, Kirk AD. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. Am J Transplant. 2016 Feb;16(2):550-64. doi: 10.1111\/ajt.13469. Epub 2015 Oct 5. PMID: 26436448; PMCID: PMC4822163.","DOI":"10.1111\/ajt.13469"},{"issue":"1","key":"10.1016\/j.humimm.2025.111620_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-017-1118-7","article-title":"B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy","volume":"15","author":"Beausang","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.humimm.2025.111620_b0180","doi-asserted-by":"crossref","unstructured":"Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int. 2014;2014:681678. doi: 10.1155\/2014\/681678. Epub 2014 Apr 29. PMID: 24877127; PMCID: PMC4022166.","DOI":"10.1155\/2014\/681678"},{"issue":"5","key":"10.1016\/j.humimm.2025.111620_b0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.2100792","article-title":"Combination CTLA4Ig and Anti-CD40 Ligand Treatment Modifies T and B Cell Metabolic Profiles and Promotes B Cell Receptor Remodeling in a Mouse Model of Systemic Lupus Erythematosus","volume":"210","author":"Raparia","year":"2023","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.humimm.2025.111620_b0190","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/TP.0b013e31819b5a58","article-title":"Assessment of belatacept-mediated costimulation blockade through evaluation of CD80\/86-receptor saturation","volume":"87","author":"Latek","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2025.111620_b0195","doi-asserted-by":"crossref","unstructured":"Ashokkumar C, Talukdar A, Sun Q, Higgs BW, Janosky J, Wilson P, Mazariegos G, Jaffe R, Demetris A, Dobberstein J, Soltys K, Bond G, Thomson AW, Zeevi A, Sindhi R. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant. 2009 Jan;9(1):179-91. doi: 10.1111\/j.1600-6143.2008.02459.x. Epub 2008 Oct 31. PMID: 18976293; PMCID: PMC2997472.","DOI":"10.1111\/j.1600-6143.2008.02459.x"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592500391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592500391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:47:35Z","timestamp":1781455655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888592500391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S019888592500391X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111620","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belatacept suppresses B-cell subset alloresponses","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}],"article-number":"111620"}}